Steven Kelly, Carisma Therapeutics CEO

Con­tin­u­ing push be­yond Covid-19 vac­cines, Mod­er­na part­ners with 'CAR-M' biotech on in vi­vo can­cer cell ther­a­pies

Since com­ing in­to a mas­sive wind­fall with its Covid-19 vac­cines, Mod­er­na has been look­ing for ways to ex­pand its mR­NA tech­nolo­gies in­to oth­er promis­ing ar­eas. On Mon­day, the biotech took its next step to­ward that goal.

Mod­er­na is part­ner­ing with Caris­ma Ther­a­peu­tics on a huge slate of “CAR-M” pro­grams to treat can­cer, the com­pa­nies an­nounced Mon­day morn­ing, promis­ing $45 mil­lion up­front and $35 mil­lion in eq­ui­ty. Though the amount of mile­stones was not spec­i­fied, the biotechs not­ed Mod­er­na has the op­tion to nom­i­nate up to 12 tar­gets for de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA